PL228155B1 - 3-{(3R, 4R)-4 -metylo -3-[metylo-(7H -pirolo[2, 3 -d]pirymidyn -4- ylo)-amino]-piperydyn -1-ylo}-3 -okso -propionitryl - Google Patents
3-{(3R, 4R)-4 -metylo -3-[metylo-(7H -pirolo[2, 3 -d]pirymidyn -4- ylo)-amino]-piperydyn -1-ylo}-3 -okso -propionitrylInfo
- Publication number
- PL228155B1 PL228155B1 PL409305A PL40930502A PL228155B1 PL 228155 B1 PL228155 B1 PL 228155B1 PL 409305 A PL409305 A PL 409305A PL 40930502 A PL40930502 A PL 40930502A PL 228155 B1 PL228155 B1 PL 228155B1
- Authority
- PL
- Poland
- Prior art keywords
- methyl
- compound
- pyrrolo
- salts
- grams
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29477501P | 2001-05-31 | 2001-05-31 | |
| US60/294,775 | 2001-05-31 | ||
| US34104801P | 2001-12-06 | 2001-12-06 | |
| PCT/IB2002/001905 WO2002096909A1 (en) | 2001-05-31 | 2002-05-29 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| US60/341,048 | 2011-12-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL409305A1 PL409305A1 (pl) | 2014-12-22 |
| PL228155B1 true PL228155B1 (pl) | 2018-02-28 |
Family
ID=26968730
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL409305A PL228155B1 (pl) | 2001-05-31 | 2002-05-29 | 3-{(3R, 4R)-4 -metylo -3-[metylo-(7H -pirolo[2, 3 -d]pirymidyn -4- ylo)-amino]-piperydyn -1-ylo}-3 -okso -propionitryl |
| PL02367945A PL367945A1 (en) | 2001-05-31 | 2002-05-29 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02367945A PL367945A1 (en) | 2001-05-31 | 2002-05-29 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
Country Status (52)
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| EP1294724B1 (en) * | 2000-06-26 | 2006-04-19 | Pfizer Products Inc. | Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| JP2005539041A (ja) * | 2002-08-27 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Ｒａｆキナーゼ阻害剤としてのグリシンアミド誘導体 |
| CA2507392A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
| US20090163523A1 (en) * | 2004-05-03 | 2009-06-25 | Philip Lake | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| EP1768982A2 (en) | 2004-06-29 | 2007-04-04 | Amgen Inc. | Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity |
| WO2006017443A2 (en) | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
| CN101106983A (zh) * | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
| KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| ATE540952T1 (de) * | 2005-07-29 | 2012-01-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese |
| EP1926735A1 (en) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| SI2455382T1 (sl) | 2005-12-13 | 2017-03-31 | Incyte Holdings Corporation | S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| ES2467665T5 (es) | 2007-06-13 | 2022-11-03 | Incyte Holdings Corp | Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| WO2009007839A1 (en) * | 2007-07-11 | 2009-01-15 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| EP2288610B8 (en) | 2008-03-11 | 2016-10-12 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as jak inhibitors |
| AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| MX2011001259A (es) * | 2008-08-01 | 2011-03-15 | Biocryst Pharm Inc | Derivados de piperidina como inhibidores jak3. |
| EP2384326B1 (en) * | 2008-08-20 | 2014-04-23 | Zoetis LLC | Pyrrolo[2,3-d]pyrimidine compounds |
| CA2752150A1 (en) * | 2009-02-11 | 2010-08-19 | Reaction Biology Corp. | Selective kinase inhibitors |
| AU2010239396B2 (en) | 2009-04-20 | 2016-06-23 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of Janus Kinase 3 |
| PT2432472T (pt) | 2009-05-22 | 2019-12-09 | Incyte Holdings Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrilo como inibidores de jak |
| MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CN102596962A (zh) * | 2009-09-10 | 2012-07-18 | 弗·哈夫曼-拉罗切有限公司 | Jak抑制剂 |
| CA2777114C (en) | 2009-10-09 | 2018-10-23 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CN102574860A (zh) | 2009-10-15 | 2012-07-11 | 辉瑞大药厂 | 吡咯并[2,3-d]嘧啶化合物 |
| EP2513114B1 (en) | 2009-12-18 | 2014-04-02 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| US8461328B2 (en) * | 2010-01-12 | 2013-06-11 | Genentech, Inc. | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| US20120309776A1 (en) | 2010-02-05 | 2012-12-06 | Pfitzer Inc. | Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors |
| MX354212B (es) | 2010-03-10 | 2018-02-19 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| US20110288107A1 (en) | 2010-05-21 | 2011-11-24 | Bhavnish Parikh | Topical formulation for a jak inhibitor |
| EP2635557A2 (en) | 2010-11-01 | 2013-09-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2481397A1 (en) | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Pharmaceutical compositions comprising tasocitinib |
| EP2481411A1 (en) | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
| US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
| EP2691395B1 (en) | 2011-03-28 | 2017-08-30 | ratiopharm GmbH | Processes for preparing tofacitinib salts |
| US9050342B2 (en) | 2011-03-29 | 2015-06-09 | Pfizer Inc. | Beneficial effects of combination therapy on cholesterol |
| CN103459394B (zh) * | 2011-04-08 | 2016-04-27 | 辉瑞大药厂 | 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物 |
| EP2524688B1 (en) | 2011-05-11 | 2013-05-01 | ratiopharm GmbH | Composition for modified release comprising ranolazine |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| HK1198579A1 (en) | 2011-08-10 | 2015-04-30 | Novartis Pharma Ag | Jak p13k/mtor combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| CA2856301C (en) | 2011-11-23 | 2020-10-06 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| EP3750544B1 (en) * | 2011-11-30 | 2025-03-05 | Emory University | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| EP3170826A1 (en) | 2011-12-15 | 2017-05-24 | ratiopharm GmbH | Tofacitinib mono-malate salt |
| WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| CN104837817B (zh) | 2012-07-25 | 2017-03-22 | 力奇制药公司 | 制备3‑氨基‑哌啶化合物的合成路线 |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| ES2880814T3 (es) | 2012-11-15 | 2021-11-25 | Incyte Holdings Corp | Formas de dosificación de liberación sostenida de ruxolitinib |
| CN104955803B (zh) * | 2012-11-30 | 2017-11-28 | 斯洛文尼亚莱柯制药股份有限公司 | 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物 |
| WO2014097150A1 (en) | 2012-12-17 | 2014-06-26 | Ranbaxy Laboratories Limited | Process for the preparation of tofacitinib and intermediates thereof |
| EP2938616A4 (en) | 2012-12-28 | 2016-06-15 | Glenmark Pharmaceuticals Ltd | PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF |
| ES2713052T3 (es) | 2013-02-22 | 2019-05-17 | Pfizer | Combinación de derivados de pirrolo[2,3-d]pirimidina con uno o más agentes adicionales como inhibidores de janus cinasas (JAK) |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2014174073A1 (en) | 2013-04-26 | 2014-10-30 | Sandoz Ag | Sustained release formulations of tofacitinib |
| TWI789516B (zh) | 2013-08-07 | 2023-01-11 | 美商英塞特公司 | Jak1抑制劑之持續釋放劑型 |
| CN104513248B (zh) * | 2013-09-30 | 2019-05-24 | 重庆医药工业研究院有限责任公司 | 一种托法替尼中间体的纯化方法 |
| MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
| HUE042911T2 (hu) * | 2013-12-09 | 2019-07-29 | Unichem Lab Ltd | Javított eljárás a (3R,4R)-(1-benzil-4-metil-piperidin-3-il)-metilamin elõállítására |
| CA2881262A1 (en) | 2014-02-06 | 2015-08-06 | Prabhudas Bodhuri | Solid forms of tofacitinib salts |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| ES2750655T3 (es) | 2014-08-12 | 2020-03-26 | Pfizer | Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa |
| CA2979425C (en) | 2015-01-20 | 2020-04-14 | Wuxi Fortune Pharmaceutical Co., Ltd | Jak inhibitor |
| WO2016133317A1 (ko) * | 2015-02-17 | 2016-08-25 | (주)아모레퍼시픽 | Ｎ-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법 |
| CN104761556B (zh) * | 2015-03-21 | 2017-06-23 | 河北国龙制药有限公司 | 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法 |
| EP3078665A1 (en) * | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
| JP6600365B2 (ja) | 2015-04-29 | 2019-10-30 | 无▲錫▼福祈制▲薬▼有限公司 | Ｊａｋ阻害剤 |
| US10703756B2 (en) | 2015-05-01 | 2020-07-07 | Pfizer Inc. | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof |
| EP3305788B1 (en) | 2015-05-29 | 2020-08-05 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase inhibitor |
| BR112017013253A2 (pt) * | 2015-07-27 | 2018-02-27 | Unichem Laboratories Limited | comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes |
| KR101771219B1 (ko) * | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
| CN108472298B (zh) | 2015-11-24 | 2021-04-20 | 深圳阿拉丁医疗科技有限公司 | 选择性激酶抑制剂 |
| CN105348287A (zh) * | 2015-11-30 | 2016-02-24 | 宁波立华制药有限公司 | 一种枸橼酸托法替布的新型合成工艺 |
| KR102565407B1 (ko) * | 2016-01-04 | 2023-08-10 | (주)아모레퍼시픽 | 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법 |
| WO2017125417A1 (en) | 2016-01-18 | 2017-07-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Tofacitinib as vaccination immune modulator |
| WO2018004306A1 (en) | 2016-06-30 | 2018-01-04 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
| KR102398659B1 (ko) | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
| CN107602569A (zh) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途 |
| KR102078805B1 (ko) | 2017-11-30 | 2020-02-19 | 보령제약 주식회사 | 토파시티닙을 포함하는 약제학적 조성물 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| IL275207B (en) | 2017-12-28 | 2022-09-01 | Daewoong Pharmaceutical Co Ltd | An oxy-fluoropiperidine derivative as a kinase inhibitor |
| HRP20220510T1 (hr) | 2018-01-30 | 2022-05-27 | Incyte Corporation | Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona) |
| US12161748B2 (en) | 2018-01-31 | 2024-12-10 | Twi Biotechnology, Inc. | Topical formulations comprising tofacitinib |
| CN111670036B (zh) * | 2018-01-31 | 2024-08-09 | 安成生物科技股份有限公司 | 包含托法替尼的局部调配物 |
| HUE067471T2 (hu) | 2018-03-30 | 2024-10-28 | Incyte Corp | Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával |
| KR102131107B1 (ko) * | 2019-01-15 | 2020-07-07 | 주식회사 다산제약 | 3-아미노-피페리딘 화합물의 신규한 제조 방법 |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| WO2020172714A1 (en) | 2019-02-27 | 2020-09-03 | Samson Clinical Pty Ltd | Treatment of autoimmune disease |
| US12269830B2 (en) | 2019-03-13 | 2025-04-08 | Intas Pharmaceuticals Ltd. | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof |
| CN113993585B (zh) | 2019-03-27 | 2024-10-01 | 英矽智能科技知识产权有限公司 | 双环jak抑制剂及其用途 |
| US12227478B2 (en) | 2019-04-05 | 2025-02-18 | Yuhan Corporation | Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same |
| US20220378707A1 (en) | 2019-11-14 | 2022-12-01 | Pfizer Inc. | 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms |
| US20220389010A1 (en) * | 2019-11-25 | 2022-12-08 | Daewoong Pharmaceutical Co., Ltd. | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same |
| WO2021198980A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20240166651A1 (en) * | 2021-03-15 | 2024-05-23 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
| CN113549075B (zh) * | 2021-06-23 | 2025-09-23 | 合肥华方医药科技有限公司 | 一种枸橼酸托法替布非对映异构体杂质的合成方法 |
| EP4180042A1 (en) | 2021-11-15 | 2023-05-17 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A film coated tablet comprising micronized tofacitinib |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| US5389509A (en) | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| JPH07330732A (ja) * | 1994-06-10 | 1995-12-19 | Kyorin Pharmaceut Co Ltd | 光学活性な３−アミノ−１−ベンジルピペリジン誘導体 |
| US6136596A (en) * | 1995-05-19 | 2000-10-24 | University Of Massachusetts | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| PT831829E (pt) | 1995-06-07 | 2003-12-31 | Pfizer | Derivados de pirimidina heterociclicos de aneis fundidos |
| WO1997002262A1 (en) | 1995-07-05 | 1997-01-23 | E.I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
| HUP9900330A3 (en) | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| EA000072B1 (ru) | 1995-11-14 | 1998-06-25 | Фармация Энд Апджон С.П.А. | Бициклическое конденсированное пиримидиновое соединение и его применение в качестве терапевтического агента |
| ES2177925T3 (es) | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
| WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| WO1998002437A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| US6413971B1 (en) | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
| ATE391719T1 (de) | 1997-02-05 | 2008-04-15 | Warner Lambert Co | Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation |
| EP0972197A1 (en) | 1997-03-24 | 2000-01-19 | PHARMACIA & UPJOHN COMPANY | Method for identifying inhibitors of jak2/cytokine receptor binding |
| JP2002510687A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ |
| HUP0102793A3 (en) | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
| CZ20004727A3 (cs) | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法 |
| HUP0103386A3 (en) | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| EP1294724B1 (en) | 2000-06-26 | 2006-04-19 | Pfizer Products Inc. | Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| EP1768982A2 (en) * | 2004-06-29 | 2007-04-04 | Amgen Inc. | Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity |
-
2002
- 2002-05-23 US US10/154,699 patent/US7301023B2/en not_active Expired - Lifetime
- 2002-05-29 EP EP02733058A patent/EP1392694A1/en not_active Withdrawn
- 2002-05-29 SK SK1465-2003A patent/SK288199B6/sk unknown
- 2002-05-29 MX MXPA03011062A patent/MXPA03011062A/es active IP Right Grant
- 2002-05-29 CN CNA028108175A patent/CN1729192A/zh active Pending
- 2002-05-29 TW TW092133699A patent/TWI316061B/zh not_active IP Right Cessation
- 2002-05-29 HR HR20030943A patent/HRP20030943B1/xx not_active IP Right Cessation
- 2002-05-29 OA OA1200300308A patent/OA12612A/en unknown
- 2002-05-29 WO PCT/IB2002/001905 patent/WO2002096909A1/en not_active Ceased
- 2002-05-29 PE PE2002000452A patent/PE20030561A1/es not_active Application Discontinuation
- 2002-05-29 AT AT05015461T patent/ATE519741T1/de not_active IP Right Cessation
- 2002-05-29 KR KR1020067025590A patent/KR20060133117A/ko not_active Ceased
- 2002-05-29 SI SI200231004T patent/SI1666481T1/sl unknown
- 2002-05-29 ES ES05015461T patent/ES2369226T3/es not_active Expired - Lifetime
- 2002-05-29 TN TNPCT/IB2002/001905A patent/TNSN03128A1/fr unknown
- 2002-05-29 KR KR1020077025832A patent/KR100868814B1/ko not_active Expired - Lifetime
- 2002-05-29 TW TW091111480A patent/TWI310384B/zh active
- 2002-05-29 HU HUP0400152A patent/HU230876B1/hu active Protection Beyond IP Right Term
- 2002-05-29 UA UA20031110841A patent/UA80093C2/uk unknown
- 2002-05-29 KR KR1020067001821A patent/KR100869409B1/ko not_active Expired - Lifetime
- 2002-05-29 CA CA002448281A patent/CA2448281C/en not_active Expired - Lifetime
- 2002-05-29 GE GE5361A patent/GEP20063784B/en unknown
- 2002-05-29 EA EA200301193A patent/EA007251B1/ru active Protection Beyond IP Right Term
- 2002-05-29 CZ CZ2003-3260A patent/CZ304366B6/cs not_active IP Right Cessation
- 2002-05-29 ES ES05015454T patent/ES2393385T3/es not_active Expired - Lifetime
- 2002-05-29 BR BR0209246-8A patent/BR0209246A/pt not_active Application Discontinuation
- 2002-05-29 NZ NZ540332A patent/NZ540332A/en not_active IP Right Cessation
- 2002-05-29 JP JP2003500088A patent/JP4381137B2/ja not_active Expired - Lifetime
- 2002-05-29 PL PL409305A patent/PL228155B1/pl unknown
- 2002-05-29 RS YU92303A patent/RS52144B/sr unknown
- 2002-05-29 KR KR1020087018519A patent/KR100926875B1/ko not_active Expired - Lifetime
- 2002-05-29 KR KR10-2003-7015681A patent/KR20040003037A/ko not_active Ceased
- 2002-05-29 AU AU2002304401A patent/AU2002304401C1/en not_active Expired
- 2002-05-29 SK SK50033-2011A patent/SK288192B6/sk active Protection Beyond IP Right Term
- 2002-05-29 DK DK05015454.1T patent/DK1666481T3/da active
- 2002-05-29 EE EEP200300594A patent/EE05332B1/xx active Protection Beyond IP Right Term
- 2002-05-29 NZ NZ530380A patent/NZ530380A/en not_active IP Right Cessation
- 2002-05-29 PL PL02367945A patent/PL367945A1/xx unknown
- 2002-05-29 EP EP05015454.1A patent/EP1666481B9/en not_active Expired - Lifetime
- 2002-05-29 EA EA200600575A patent/EA012666B1/ru active Protection Beyond IP Right Term
- 2002-05-29 EP EP05015461A patent/EP1609781B1/en not_active Expired - Lifetime
- 2002-05-29 IL IL15858802A patent/IL158588A0/xx active IP Right Grant
- 2002-05-29 PT PT50154541T patent/PT1666481E/pt unknown
- 2002-05-30 GT GT200200100A patent/GT200200100A/es unknown
- 2002-05-30 UY UY27317A patent/UY27317A1/es not_active Application Discontinuation
- 2002-05-30 GT GT200200100AK patent/GT200200100AA/es unknown
- 2002-05-30 PA PA20028546301A patent/PA8546301A1/es unknown
- 2002-05-30 MY MYPI20021988A patent/MY129649A/en unknown
- 2002-05-30 AR ARP020102017A patent/AR037321A1/es not_active Application Discontinuation
- 2002-05-31 AP APAP/P/2002/002550A patent/AP1859A/en active
-
2003
- 2003-10-13 IS IS6993A patent/IS3023B/is unknown
- 2003-10-13 CU CU20030229A patent/CU23337B7/es not_active IP Right Cessation
- 2003-10-14 ZA ZA200307982A patent/ZA200307982B/en unknown
- 2003-11-21 MA MA27410A patent/MA27029A1/fr unknown
- 2003-11-24 NO NO20035201A patent/NO328578B1/no not_active IP Right Cessation
- 2003-11-26 EC EC2003004865A patent/ECSP034865A/es unknown
- 2003-11-27 BG BG108389A patent/BG66489B1/bg unknown
-
2004
- 2004-05-07 AR ARP040101561A patent/AR045680A2/es unknown
- 2004-06-16 US US10/869,101 patent/US7432370B2/en not_active Expired - Lifetime
-
2008
- 2008-03-14 CL CL200800762A patent/CL2008000762A1/es unknown
- 2008-07-16 AU AU2008203170A patent/AU2008203170B2/en active Active
- 2008-07-24 CR CR10177A patent/CR10177A/es unknown
-
2009
- 2009-10-13 NO NO20093135A patent/NO20093135L/no not_active Application Discontinuation
-
2012
- 2012-11-09 CY CY20121101069T patent/CY1113322T1/el unknown
-
2017
- 2017-08-02 NL NL300887C patent/NL300887I2/nl unknown
- 2017-08-08 LT LTPA2017025C patent/LTC1666481I2/lt unknown
- 2017-08-09 LU LU00031C patent/LUC00031I2/fr unknown
- 2017-08-17 BE BE2017C032C patent/BE2017C032I2/fr unknown
- 2017-09-01 CY CY2017028C patent/CY2017028I1/el unknown
- 2017-09-04 FR FR17C1031C patent/FR17C1031I2/fr active Active
- 2017-09-08 NO NO2017047C patent/NO2017047I1/no unknown
-
2019
- 2019-02-19 HU HUS1900008C patent/HUS1900008I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL228155B1 (pl) | 3-{(3R, 4R)-4 -metylo -3-[metylo-(7H -pirolo[2, 3 -d]pirymidyn -4- ylo)-amino]-piperydyn -1-ylo}-3 -okso -propionitryl | |
| CN1325498C (zh) | 新型结晶化合物 | |
| EP1235830B1 (en) | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS | |
| HK1070653B (zh) | 新型结晶化合物 |